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Abstract
Purpose: Survival of acute leukemia (AL) patients following
umbilical cord blood transplantation (UCBT) is dependent on an
array of individual features. Integrativemodels for risk assessment
are lacking. We sought to develop a scoring system for prediction
of overall survival (OS) and leukemia-free survival (LFS) at 2 years
following UCBT in AL patients.
Experimental Design: The study cohort included 3,140
pediatric and adult AL UCBT patients from the European
Society of Blood and Marrow Transplantation and Eurocord
registries. Patients received single or double cord blood
units. The dataset was geographically split into a derivation
(n ¼ 2,362, 65%) and validation set (n ¼ 778, 35%).
Top predictors of OS were identiﬁed using the Random
Survival Forest algorithm and introduced into a Cox regres-
sion model, which served for the construction of the UCBT
risk score.
Results: The score includes nine variables: disease status, diag-
nosis, cell dose, age, center experience, cytomegalovirus serosta-
tus, degree of HLA mismatch, previous autograft, and anti-
thymocyte globulin administration. Over the validation set an
increasing score was associated with decreasing probabilities for
2 years OS and LFS, ranging from 70.21% [68.89–70.71, 95%
conﬁdence interval (CI)] and 64.76% (64.33–65.86, 95% CI) to
14.78% (10.91–17.41) and 18.11% (14.40–22.30), respectively.
It stratiﬁed patients into six distinct risk groups. The score's
discrimination (AUC) over multiple imputations of the valida-
tion setwas 68.76 (68.19–69.04, range) and65.78 (65.20–66.28)
for 2 years OS and LFS, respectively.
Conclusions: The UCBT score is a simple tool for risk strati-
ﬁcation of AL patients undergoingUCBT.Widespread application
of the scorewill require further independent validation.ClinCancer
Res; 23(21); 6478–86. 2017 AACR.
Introduction
Umbilical cord blood (UCB) is an established alternative
source of hematopoietic stem cells for allogeneic transplanta-
tion when suitable HLA-matched sibling, or well-matched
unrelated donors are unavailable (1). It may offer a cure for
patients with acute leukemia (AL). Mounting experience with
unrelated UCB transplantation (UCBT), modiﬁcations of con-
ditioning regimens, and better choice of the UCB unit accord-
ing to cell dose and HLA typing have led to improved outcomes
(2). Various studies have linked individual parameters such as
recipient's disease status, cell dose, degree of HLA match, graft
type (single vs. double), and anti-thymocyte globulin (ATG)
administration with mortality following UCBT (3–11). How-
ever, it remains unclear how these parameters should be best
combined to optimize transplantation outcomes and obtain
prognostic information. Furthermore, integrative models for
prediction of UCBT outcomes are lacking.
We investigated a series of UCBT parameters, evaluating
their individual and cumulative predictive weight in the pre-
diction of overall survival (OS) at 2 years following transplan-
tation in a large cohort of AL patients. Based on the top
predictors, a risk score for 2 years OS and leukemia-free
survival (LFS) was constructed.
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Materials and Methods
Source of data and participants
This was a retrospective prognostic modeling study. The data
source was based on information reported to Eurocord and the
Acute LeukemiaWorking Party, Paediatric DiseaseWorking Party,
and Cord Blood Committee of the European Society for Blood
and Marrow Transplantation (EBMT). The EBMT registry is a
voluntary working group of more than 500 transplant centers,
whose participants routinely report data on patients undergoing
hematopoietic stem cell transplantation (HSCT). Eurocord col-
lects data on UCBT performed in >50 countries, mainly in EBMT
centers. The population selection criteria included children and
adults undergoing an UCBT (single/double unit) between the
years 2004 and 2014, as a treatment for de novo or secondary AL in
all disease statuses. Patients receiving myeloablative (MAC) or
reduced intensity conditioning regimen (RIC) were included.
MAC was deﬁned as a regimen containing either total body
irradiation (TBI) with a dose greater than 6 Gy, a total dose of
oral Busulfan greater than 8 mg/kg, or a total dose of intravenous
Busulfan greater than6.4mg/kg (11). Patientswhohad a previous
allogeneic HSCT were excluded. All patients or legal guardians
provided informed consent for UCBT according to the Declara-
tion of Helsinki. The review board of Eurocord/EBMT approved
this study.
To maximize the power and generalizability of the results, all
available patients on the registry were included, provided they
meet inclusion criteria and had no missing data on the measured
outcome. Geographical splitting (i.e., random selection of the
center's country; Supplementary Table S1)was applied to generate
the derivation (n¼ 2,362, 65%) and validation datasets (n¼ 778,
35%) from the original cohort (i.e., geographical validation;
ref. 12).
Predictors and outcomes
Nineteen variables detailing patient disease and UCB charac-
teristics were considered (Table 1). These include, recipients' age,
sex, recipient cytomegalovirus (CMV) serostatus, and Karnofsky/
Lansky performance status at UCBT (<80, 80), diagnosis [acute
myeloid leukemia (AML) or acute lymphoblastic leukemia
(ALL)], disease status [ﬁrst complete remission (CR), second CR,
>second CR, advanced (i.e., active disease), months from diag-
nosis to transplantation, cytogenetics (good, intermediate, poor,
or secondary AL); refs. 13, 14], previous autologous HSCT, graft
type [single or double cord blood unit (sCBU or dCBU),
respectively], total nucleated cells/kg body weight (TNC) at cryo-
preservation, degree of HLA mismatch as deﬁned by antigen or
allelic level DNA typing (1, >1), donor–recipient ABO blood
group match (major incompatibility, other), female donor to
male recipient, mycophenolate mofetil for GVHD prophylaxis,
ATG administration, and center experience as measured by the
annual number of UCBT done in the individual center and
reported to Eurocord/EBMT.
The primary and secondary predictive objectives were predic-
tion of OS and LFS at 2 years following UCBT, respectively. AnOS
eventwas deﬁned as death from any cause. Patients were censored
if alive at 2 years or last follow-up. LFSwas deﬁned as survival with
no evidence of relapse or progression. Probabilities of LFS andOS
were calculated using Kaplan–Meier estimates; differences
between groups were evaluated using the log-rank test. Cumula-
tive incidence functions were used to estimate relapse incidence
and non-relapse-related mortality (NRM) in a competing risks
setting because death and relapse compete; differences between
groups were evaluated using the Fine and Gray method.
Statistical analysis pipeline
Brieﬂy, the analysis pipeline comprised of sequential stages: (i)
preprocessing- data quality assurance and multiple imputations
of missing values; (ii) estimation of predictor importance using
the random survival forest (RSF) for feature selection; (iii) inter-
action analysis usingRSF andCoxmodelization; (iv) construction
of the risk score. Principles for prognostic model development
were adapted from the Transparent Reporting of a prediction
model for Individual Prognosis Or Diagnosis (TRIPOD) state-
ment (12).
Analyses were performedwith SPSS version 21 (SPSS Inc./IBM)
and R version 3.2.1 (R Development Core Team( including the
mi, randomForestSRC, ggRandomForests, and survival packages.
Missing data
We assumed missing data occurred at random depending on
the clinical variables and UCBT outcomes, and performed mul-
tiple imputations using chained equations (15). Multiple impu-
tation allows to introduce the variability of imputed data to ﬁnd a
range of possible responses fromwhich to work from. It has been
shown to be an effective way of handling missing data and
minimizes bias and loss in precision that may often result from
excluding such patients. In addition, multiple imputation
remains valid even if the proportion of missing data is large
(12). Missing values were predicted for the entire cohort on the
basis of all predictors listed in Table 1, demographical informa-
tion on the transplant center, and patients overall survival (16). A
total of 20 imputations were performed on the entire cohort,
producing 20 distinct datasets.
Feature selection
The RSF algorithm was used to identify predictive features of
2 years OS following UCBT. RSF is an extension of random forest
machine learning algorithm to analyze right-censored time-to-
event data (17). A forest of survival trees is grown using a log-rank
splitting rule to select the optimal candidate variables. A survival
Translational Relevance
Umbilical cord blood transplantation (UCBT) is a curative
treatment for acute leukemia. Several individual features have
been associated with outcomes following transplantation, but
it remains unclear how these parameters should be best
combined to predict outcomes. We have developed the ﬁrst
integrative scoring system for predictionof overall survival and
leukemia-free survival following UCBT in acute leukemia
patients. The score stratiﬁes patients into six distinct risk
groups by weighing patient, disease, donor, and transplanta-
tion-related features. Potential applications include pretrans-
plant risk assessment and stratiﬁcation, interpretation and
analysis of retrospective data, patient counseling during
informed consent sessions, and tailoring transplant regimens
or referring to alternative treatments according to transplan-
tation risk.
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estimate for each observation is constructed with a Kaplan–Meier
estimator within each terminal node and at each event time. RSF
models can be used for prediction and knowledge extraction,
including variable ranking and recovery of nonlinear effects
and interactions, as they are fully non-parametric (18, 19). The
predictive accuracy of an RSF model is assessed by the Harrell
concordance (C)-index. It is a measure of discrimination
obtained by repetitive bootstrapping (1,000 iterations) when
constructing the forest and is conceptually similar to the area
under the receiver-operating characteristic curve (AUC), ranging
from 0.5 to 1.
Minimal depth, a property derived from the construction of
each tree within the forest can be used for predictor ranking.
Minimal depth assumes that variables with high impact on the
Table 1. Patients characteristics
Variable Value Missing (%)
UCBT year Median (IQR) 2,009 (2007–2012)






Karnofsky/Lansky PS 765 (24)
<80% 110 (4.6%)
80 2,265 (95.4%)









Secondary AL 178 (7.9)
Months from diagnosis to UCBT Median (IQR) 10.5 (5.82–22.44) 83 (3)
12 1,668 (54.6)
>12 1,389 (45.4)
Previous autograft 0 (0)
No 2,944 (93.8)
Yes 196 (6.2)
Disease status 197 (6)
First CR 1,332 (45.3)
Second CR 1,071 (36.4)
Other CR 159 (5.4)
Advanced disease 381 (12.9)
Graft 0 (0)
Single CB unit 2,139 (68.1)
Double CB unit 1,001 (31.9)
HLA mismatch 640 (20)
1 1,179 (47.2)
>1 1,321 (52.8)
ABO major vs. other 0 (0)
Other 2,281 (72.6)
Major incompatibility 859 (27.4)
Female donor to male recipient 89 (3)
No 2,182 (71.9)
Yes 959 (31.4)









Mycophenolate mofetil 384 (12)
No 1,226 (44.5)
Yes 1,530 (55.5)
Center experience (UCBT/year) Median (IQR) 30 (12–53) 0 (0)
<20 1,150 (36.6)
20 1,990 (63.4)
Abbreviation: PS, performance status.
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prediction are those thatmost frequently split nodes nearest to the
trunks of the trees (i.e., at the root node)where they partition large
samples of the populations. Predictiveness of a variable is inverse-
ly related to the value of minimal depth. Smaller minimal depth
value of a variable, the greater is its predictive impact (20). RSF
and minimal depth are further explained in Appendix 1.
For all 20 versions of the imputed derivation datasets, we
constructed comprehensive RSF models, using all available vari-
ables, for prediction of 2 years OS. The importance of variables in
each model was determined using the minimal depth method. A
list of variables, ordered by average importance across models is
presented in Supplementary Fig. S1.
A threshold for variable importance was determined through a
nested RSF approach (21), estimating a cut-off for predictive
contribution by serially introducing variables into RSF models
according to their importance, while measuring improvement in
the C-index. For instance, in the ﬁrst iteration, the top ranking
variable was introduced; in the second, the top two variables; and
so on. Variables were considered informative as long as the
predictive performance improved.
Interaction analysis
Interactions were analyzed using partial dependence condi-
tional plots (coplots). Partial dependence plots are generated by
isolating the effects of variables other than the covariate of
interest. This provides a qualitative, risk-adjusted visualization
of the nature (e.g., linear, nonlinear, etc.) of a variable's effect on
predicted response (17, 18). Coplots are in fact partial depen-
dence plots conditioned on group membership (18). All inter-
actions discovered by coplots were also validated by Cox mod-
elization (P < 0.1). Interacting variables were combined to form
groups based on joint values of the interacting variables.
Risk score construction
The top predictors and grouped interactions were intro-
duced into a Cox model. Hazard ratio estimates were pooled
over 20 imputed derivation datasets using Rubin's rules (22).
The weight for each predictor was determined according the
hazard ratio (HR ¼ 1–1.49 ¼ 1; HR ¼ 1.5–2.49 ¼ 2; HR ¼ 2.5–
3.49 ¼ 3), providing P < 0.1. The score was categorized, and
intervals representing outliers were grouped. The associated
risk for 2 years OS, LFS, NRM, and relapse incidence was
calculated and plotted on a randomly selected imputed der-
ivation dataset and its corresponding validation set (i.e., the
derivation and validation sets were produced in the same
iteration of the multiple imputation process). Calibration
and discrimination, assessed with the time-dependent AUC
(12, 23), were used to evaluate the score's quality.
Results
Patient characteristics and outcomes
Characteristics of 3,140 analyzed patients are listed in Table 1.
Median age was 21.9 years (interquartile range [IQR]: 7.3–43.8).
The majority of patients had AML (55.5%) were in ﬁrst CR (CR1;
45.2%) and received MAC (71.9%). Grafts were mainly derived
from a sCBU (68.1%) and had at least two HLA mismatches
(52.8%).Median follow-upwas30months. The2 yearsOS,NRM,
relapse incidence, and LFS rates were 47.7% (95%CI, 45.8–49.6),
29.9% (95% CI, 28.2–31.6), 26.8% (95% CI, 25.1–28.4) and
43.4% (95% CI, 41.5–45.2), respectively.
Predictor identiﬁcation and ranking
Minimal depth, a dimensionless order statistic measuring the
predictiveness of a variable in a survival tree, was used to estimate
variable importance across the derivation datasets (Appendix 1).
Disease status was consistently the most inﬂuential factor, fol-
lowed by age and cell dose (TNCs cryopreserved; Supplementary
Fig. S1). To determine a cut off for the variables' cumulative
predictive contribution (i.e., the minimum number of variables
required maximal predictive performance), a nested RSF
approach was applied (21). RSF prediction models were con-
structed on serially introduced variables, according to their min-
imal depth ranking. Predictive performance on the derivation
datasets, as measured by the C-index, incrementally improved
until reaching a plateau after introducing the top 10 ranked
variables (disease status, TNCs cryopreserved, age, center experi-
ence, interval from diagnosis to UCBT, year of UCBT, CMV
serostatus, degree of HLAmismatch, previous autograft, and ATG
administration; Fig. 1).
The UCBT risk score
For the score construction, we introduced the top predictors of
2 years overall survival into a Cox multivariate model. Age, cell
dose (TNCs cryopreserved) and center experience were catego-
rized into two groups according to acceptable thresholds (7, 24).
Although not considered among top predictors, we included
diagnosis into the model, as it carries important clinical infor-
mation. The score was developed on all 20 versions of the
imputed derivation datasets. In a preliminary phase, a randomly
selected version of one of the imputed derivation datasets was
used to analyze interactions; coplots derived from a RSF model
showed that increasing age was associated with inferior predicted
survival in the groups receiving ATG and that the effect of disease
status was diagnosis dependent (Supplementary Fig. S2). These
interactions were validated in a Cox model (Tables S2 and S3).
The UCBT risk score was derived from pooled estimates of Cox
models over multiple imputed datasets (Table 2; ref. 22). The
models included independent predictors and variables grouping
interactions (ATG administration conditioned on age group and
disease status conditioned on diagnosis). The variable year of
UCBT was kept in the models for covariate adjustment, but
excluded from the score. Duration from diagnosis to UCBT was
not included in theCoxmodel as it is highly dependent ondisease
and disease status, resulting in complex three-way interactions
with 16 possible combinations. Furthermore, its addition to the
Cox models had minimal impact on the model's performance
(i.e., the difference in the Akaike's Information Criterion between
the two models was 0.04%).
On a randomly selected derivation dataset and its correspond-
ing validation set (patients' characteristics are listed in Table S4),
the UCBT score ranged from 0 to 8 (Table 3). Calibration was
excellent (Supplementary Fig. S3). An increasing score corre-
sponded with increasing hazard and decreasing probability for
2 years OS and LFS (log-rank P < 0.001 for both, Table 4 and
Supplementary Table S5). Over the validation cohort, probabil-
ities of 2 years OS and LFS ranged from 70.21% (95% CI, 68.89–
70.71) and 64.76% (95% CI, 64.33–65.86), respectively, for
patients having a score of 0 to 1, to 14.78% (95% CI, 10.91–
17.41) and 18.11% (95% CI, 14.40–22.30) for a score of 6 to 8
(Fig. 2). Increasing scores were also associated with a greater
probability for 2 years NRM, ranging from 14.10% to 56.45%.
However, considerable overlap was noted between patients
Cord Blood Transplantation Scoring System
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assigned scores of 3 to 5 (Table 4). Similar results were obtained
when analyzing all versions of the imputed validation datasets
(Supplementary Table S6). Patients assigned with a score of 0 to 1
weremore likely be inﬁrst CR (78.1%), receive 3107/kgormore
TNCs (99.4%), have donors with 0 to 1 HLA mismatches
(84.3%), and be transplanted in centers performing a high num-
ber of UCBT/year (89.6%). Very high-risk patients, with scores of
6 to 8 were transplanted mainly in late CRs or advanced disease
87.3%), be adults receiving ATG (72.0%), have a donor with over
one HLAmismatch (79.9%), and transplanted in center perform-
ing 20 or less UCBT/year (60.8%; Table S7). The score's median
discrimination (AUC) for 2 years OS overall imputation of the








Previous autograft (yes vs. no) 1.39 (1.12–1.69) 0.002
HLA mismatch (>1 vs. 1) 1.22 (1.07–1.37) 0.003




UCBT year 0.97 (0.95–0.97) 0.006
Age and ATG (reference: <18 years and no ATG)
<18 years and ATG 1.04 (0.81–1.35) 0.715
18 years and no ATG 0.99 (0.76–1.28) 0.831
18 years and ATG 1.36 (1.05–1.77) 0.018
Diagnosis and disease status (reference: ALL and CR1)
ALL and CR2 1.37 (1.11–1.70) 0.004
ALL and other CR 2.53 (1.83–3.50) <0.001
ALL and advanced 3.07 (2.32–4.06) <0.001
AML and CR1 1.14 (0.93–1.39) 0.214
AML and CR2 1.24 (1.00–1.55) 0.051
AML and other CR 1.61 (1.04–2.50) 0.034
AML and advanced 2.64 (2.1–3.31) <0.001
Abbreviation: CI, conﬁdence interval.
Figure 1.
Cumulative predictive value of
variables. Variables are ordered by
predictive value as assessed with the
minimal depth method. Performance
(c-index) of nested Random Survival
Forest models, trained with an
increasing number of variables, is
plotted on the y-axis. Error bars indicate
95% conﬁdence intervals over the
imputed derivation datasets.
Improvement in performance was
observed when the top 10 variables
were added to the models, whereas
other variables (to the right of the gray
line) did not further improve the
accuracy of prediction.








Negative 0 887 (37.6) 362 (46.5)
Positive 1 1,475 (62.4) 416 (53.5)
Previous autograft
No 0 2,191 (92.8) 753 (96.8)
Yes 1 171 (7.2) 25 (3.2)
HLA mismatch
1 0 1,110 (47) 440 (56.6)
>1 1 1,252 (53) 338 (43.4)
TNC (107/kg)
TNC3 0 2,088 (88.4) 722 (92.8)
TNC<3 1 274 (11.6) 56 (7.2)
Center experience (UCBT/year)
>20 0 1,632 (69.1) 358 (46)
20 1 730 (30.9) 420 (54)
Age and ATG
Other 0 1,601 (67.8) 630 (81)
18 years and receiving ATG 1 761 (32.2) 148 (19)
Diagnosis and disease status
ALL and CR1, AML and CR1 0 1,059 (44.8) 318 (40.9)
ALL and CR2, AML and CR2 1 828 (35.1) 304 (39.1)
AML and other CR 2 44 (1.9) 19 (2.4)
ALL and other CR, ALL and advanced,
AML and advanced
3 431 (18.2) 137 (17.6)
0–1 521 (22.1) 178 (22.9)
2 559 (23.7) 208 (26.7)
3 496 (21.0) 154 (19.8)
4 344 (14.6) 110 (14.1)
5 229 (9.7) 73 (9.4)
6–8 213 (9.0) 55 (7.1)
aThe derivation and validation data sets were generated in the same iteration of
the multiple imputation process (i.e., they represent 1 out of 20 versions of
imputed data sets).
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derivation and validation datasets was 68.76 (range ¼ 68.19–
69.04) and 68.12 (range ¼ 67.43–68.69), respectively. Similarly,
for 2 years LFS themedian AUCwas 66.68 (range¼ 66.05–66.98)
and 65.78 (range ¼ 65.20–66.28), respectively.
Discussion
Umbilical cord blood transplantation is a valid alternative
source of stem cells in AL patients (25). Nonetheless, the concerns
associated with UCBT, including an increased risk of graft failure,
delayed immune reconstitution, and unavailability of the donor
for additional donationswarrants careful evaluation of transplan-
tation candidates. Motivated by the need for a predictive prog-
nostic model in UCBT, we have developed and internally vali-
dated, a risk score for 2 years overall survival and LFS following
UCBT in patients with AL. The new UCBT score is based on nine
variables; age, diagnosis, disease status, previous autologous
HSCT, recipient CMV serostatus, HLA matching, cell dose, ATG
administration, and center experience (annual UCBT/center).
This is the ﬁrst risk score developed speciﬁcally for UCBT. The
score demonstrates distinctiveness and monotonicity; it cate-
gorizes patients' survival to unique groups, and an increasing
score is associated with decreased OS and LFS.
Several scores, including the EBMT risk score, the hemato-
poietic cell transplantation comorbidity index (HCT-CI) and
the Pre-transplantation Assessment of Mortality (PAM) score
have been developed in the allogeneic HSCT setting (26–28).
These have been validated and could be incorporated in the
therapeutic algorithm of HSCT candidate assessment. Prior to
the current study, integrative prognostic models dedicated to
AL UCBT recipients were lacking. The new UCBT risk score may
serve as a prognostic tool for patient stratiﬁcation, interpreta-
tion of retrospective and prospective studies, and potentially
for treatment allocation.
The methodological process of the UCBT risk score construc-
tion was unique, involving an initial screening stage for pre-
dictors using the RSF machine learning technique, followed by
incorporation of the selected variables into a standard Cox
regression model. The integration of the two approaches is
appealing, as RSF is a nonparametric method, successfully
applied in a variety of clinical scenarios (19–21). It accounts
for censored data, refrains for assumptions on data distribu-
tion, and allows for feature selection, whereas Cox modeling is
easy to interpret and frequently used in clinical scenarios.
Overall, key principles from the TRIPOD guidelines for pre-
dictive modeling were followed, promoting standardization
and transparency in prognostic research (12).
The determinants identiﬁed by RSF and incorporated into the
UCBT score recapitulates established risk factors inUCBT.Disease
status remains the most powerful predictor (5, 24, 26), and is
diagnosis speciﬁc. The accepted threshold for graft selection,
having at least 3  107 TNC/kg and the importance of a low
degree of HLAmismatch were corroborated (7, 29). Interestingly,
an age-dependent effect of ATG was noted. Similar to ﬁndings
reported by Pascal et al., ATG had a detrimental impact among
adults in our cohort (8). However, in children, no harm was
discovered. It is likely that adults are more susceptible than
children to the risks ATG-related immune suppression (e.g.,
immune reconstitution, infections, and posttransplant lympho-
proliferative disorder). However, given ATG's potential role in
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role (8, 30, 31). In line with previous publications, the condi-
tioning regimen and graft type (single/double unit) were not
identiﬁed as risk factors (32–34), most likely reﬂecting the proper
selection of condition type and cell dose. Overall, the score
includes the main clinical risk factors impacting on UCBT out-
comes. Nonetheless, the score captures the expanding corpus of
UCBT knowledge, allowing for an integrative evaluation of trans-
plantation risk.
When dissecting the factors discriminating between patients
in differing risk score categories (Supplementary Table S7), the
importance of center experience is striking. Almost 90% of
patients receiving a score of 0 to 1 were transplanted in centers
performing 20 or more transplants per year, whereas in patients
assigned with scores of 6 to 8, only a minority (39.2%) were
transplanted in well-experienced centers. These ﬁndings stress
the importance of center experience and accreditation (35–37).
Nevertheless, patients' proﬁle could be linked to experience,
thereby introducing a selection bias; centers performing a low
volume of UCBT might resort to UCBT as last option (e.g.,
when haploidentical or 9/10 HLA unrelated donors are not
available), whereas high-volume centers may choose to pursue
UCBT as a valid option early on. Other discriminating factors
were CMV seropositivity (88.4%) and two or more than one
HLA mismatch (79.9%) in the group with the highest risk.
Patients with scores over 5 should be carefully evaluated taking
into account the associated increase in risk.
The study has several limitations. First, the UCBT score was not
validated in an external cohort. Nonetheless, geographical
Figure 2.
Survival and LFS by the UCBT risk
score.
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validation (i.e., the transplantation centers' countries in the der-
ivation and validation dataset differed) was used to ensure gen-
eralizability of the results (12). Also, the UCBT score weights were
assigned by pooling Cox estimations over multiple versions of
imputed derivation datasets (22). Second, in the registry certain
granular data are missing at least in part (e.g., disease genetic
features.)which could further improvemodels. Third, the analysis
was directed towards factors affecting 2 years OS and LFS. How-
ever, NRM incidence is of high interest, especially when compar-
ing to alternative therapies. Fourth,missing datawere imputed on
the entire cohort; interdependencies between the derivation and
validation cohort in the process of imputation could lead to
overoptimistic estimations. However, in multiple imputation
algorithms reliable prediction ofmissing data values is dependent
on the quality and extent of available data. Therefore, we opt to
maximize data exposure in the imputation process and took
measures to reduce the risk for overﬁtting, as discussed above.
Finally, categorization of continues variables introduced into the
Cox model, which was used for model construction, might have
led loss of predictive information. Nevertheless, categorization
promotes simplicity. Furthermore, the score was rather discrim-
inative, despite this transformation.
In conclusion, we have developed and internally validated the
ﬁrst risk score for stratiﬁcation of overall survival and LFS in AL
patients undergoing a UCBT. External validation is warranted for
widespread application. The score is simple and stratiﬁes patients
into distinct risk groups. Its potential applications include pre-
transplant risk assessment and stratiﬁcation, interpretation and
analysis of retrospective data, patient counseling during informed
consent sessions, and tailoring transplant regimens or referring to
alternative treatments according to transplantation risk. The
score's discrimination (i.e., AUC) is comparable to similar prog-
nostic models in HSCT (26, 28, 38); integration of detailed data
on comorbidities, transplant regimens, and the genetic features
of the disease may further enhance predictive accuracy, allowing
for individualized prediction rather than stratiﬁcation.
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